Amsterdam UMC, dept. Psychiatry
Amsterdam, North Holland, 1105 AZ, Netherlands
NCT Number: NCT06426134
The goal of this clinical trial is to learn if a ketone drink can improve signs and symptoms of patients with a schizophrenia-spectrum disorder (SSD), or a bipolar-spectrum disorder (BD).
The main questions it aims to answer are:
Does a ketone drink improve information processing in patients with SSD/BD?
Other questions it aims to answer are:
Does a ketone drink improve cognitive functioning in patients with SSD/BD? Does a ketone drink improve metabolism and inflammation in patients with SSD/BD? Does a ketone drink affect circadian rhythm in patients with SSD/BD?
Research will compare the effects of the ketone drink with that of an isocaloric carbohydrate drink in the same patients ('cross-over').
Participants will:
1. drink a ketone drink and (after a wash-out period) an isocaloric control drink (randomized order); after each drink:
* EEG/EMG to determine information-processing parameters (PPI and P300) * cognitive tests * visual analog scale of mood, energy levels, ability to focus * indirect calorimetry to determine use of energy substrate * blood draws 2. for 5 consecutive days:
* wear a continuous glucose monitor (CGM) * wear a non-invasive passive sweat biomarker sensor (EnLiSense device) * register a diet and nicotine diary * saliva sampling (max. 5x/day)
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Amsterdam, North Holland, 1105 AZ, Netherlands
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
1x50g ingestion of pure dGK
Other names: delta G Ketones (dGK)
Isocaloric carbohydrate control (active control)
Other names: Maurten Drink Mix 160
Time frame: measured 45 minutes (Tmax) after ingestion of intervention 1 (dGK) and 45 minuts after ingestion of intervention 2 (isocaloric carb control)
PPI: an event-related potential (ERP) representing information processing (known to be disrupted in schizophrenia and bipolar disorder).
The PPI task is an auditory paradigm featuring a total of 10 trials split evenly into two conditions: prepulse (PP) and non-prepulse (NP) in blocks. Startle pulses are 100dB at 40 ms, which is shown to provide significant startle visible in EEG126. Prepulse stimuli are 70 dB and 50 ms in duration, presented 50ms prior to the startle pulse. There is a 12 to 18 (avg: 15 s) interstimulus interval. All stimuli are white-noise blips. A calibrated apparatus is used to present the stimuli. Total estimated time is 20 min.
Time frame: measured 65-75 minutes after ingestion of intervention 1 (dGK) and 75 minutes after ingestion of intervention 2 (isocaloric carb control); NB: directly after PPI.
The P300 task consists of 160 stimuli in the oddball paradigm and requires the subjects to press a button on detection of the rare target (32/160). The common nontarget stimuli are 500 Hz, 100 ms duration. The rare target stimuli are 700 Hz. Both are 100 ms duration at 80 dB with variable interstimulus interval of 1.2 to 1.5 s. Preceded by 10 practice trials. This task has minimal burden and requires about 10 minutes.
Time frame: measured 75-85 minutes after ingestion of intervention 1 (dGK) and 75 minutes after ingestion of intervention 2 (isocaloric carb control); NB: directly after P300.
15WT is a measure of verbal/episodic memory. The 15WT consists of 15 words, which have to be learned during three trials. After every trial the respondent is asked to recall as many words as possible. After a distraction period of 20 minutes, the respondent is asked to name the words they have learned before, again.
Immediate recall after 1 test: maximum 15 words (minimum 0) Immediate recall after 3 test: maximum 45 words (minimum 0).
Retention score after 20 minutes:
Higher 15WT scores indicate better verbal/episodic memory, lower scores the opposite.
Time frame: measured 75-85 minutes after ingestion of intervention 1 (dGK) and 75 minutes after ingestion of intervention 2 (isocaloric carb control); NB: directly after P300.
TMT-A is a measure of (visual) attention. TMT-A outcome is the duration of time required to finalize test (including the time needed for the correction of errors prompted by the examiner), with a maximum of 5 minutes.
The average TMT-A score in healthy adults is 29 seconds; a deficient score is greater than 78 seconds.
Higher scores on TMT-A indicate worse (visual) attention.
Time frame: measured 75-85 minutes after ingestion of intervention 1 (dGK) and 75 minutes after ingestion of intervention 2 (isocaloric carb control); NB: directly after TMT-A.
TMT-B is a measure of (frontal) executive functioning. TMT-B outcome is the duration of time required to finalize test (including the time needed for the correction of errors prompted by the examiner), with a maximum of 5 minutes.
Average TMT-B score is 75 seconds; a deficient score is greater than 273 seconds.
Higher scores on TMT-B indicate worse (frontal) executive functioning.
Time frame: measured 75-85 minutes after ingestion of intervention 1 (dGK) and 75 minutes after ingestion of intervention 2 (isocaloric carb control); NB: directly after TMT-B.
DST is a measure for working memory. DST outcome is the maximum number of sequential digits correctly reproduced. In average healthy adults, the digit span is around 7 +/- 2. Minimum score is 0, maximum score is 9.
Lower DST score indicate worse working memory.
Time frame: measured circa 120 minutes after ingestion of intervention 1 (dGK) and circa 120 minutes after ingestion of intervention 2 (isocaloric carb control)
visual analog scale (VAS) is used with a scale of 0 to 10 to measure patient-experiences effects of the interventions on their mood (0=extremely depression, 10 = extremely happy/euforic), energy level (0=completely exhauster, 10= extremely energetic) and ability to focus (0=completely unable to focus, 10=perfect focus).
Time frame: first blood sample before ingestion (dGK or isocaloric control) (T0), then every 20 minutes in first hour after ingestion; afterwards every 30 minutes (max. 3 hours)
sequential blood sampling through intravenous line: concentration (pg/ml) of inflammatory biomarkers relevant for immune function:
Comparison between dGK and isocaloric control at the same time points (see below).
Time frame: first blood sample before ingestion (dGK or isocaloric control) (T0), next at T0+90 minutes
RNA expression analysis (immune panel nCounter, Nanostring) in whole blood: comparison dGK vs isocaloric control only at T0 plus 90 minutes.
Time frame: Full 5 days of the study
continuous measurement of IL-6 (pg/ml) in passive sweat (EnLiSense device)
Time frame: Full 5 days of study
continuous measurement of TNF-a (pg/ml)in passive sweat (EnLiSense device)
Time frame: circa 90-120 minutes after ingestion of intervention 1 (dGK) and intervention 2 (isocaloric control); directly after finalizing cognitive tests.
Resting energy expenditure (REE) is measured by gaseous exchange (indirect calorimetry). Oxygen consumption and CO2 production are measured during 20 minutes using a ventilated hood system (Q-NRG, Cosmed). Subjects lie flat on their backs and breathe into a canopy for 20 minutes. REE and Respiratory Quotient (RQ) are calculated with these measurements. The RQ represents the ratio of CO2 exhaled to the amount of 02 consumed by the individual and represents whole body substrate oxidation (glucose, fat and protein oxidation).
Time frame: first blood sample before ingestion (both dGK and isocaloric control) (T0), then every 20 minutes in first hour after ingestion; afterwards every 30 minutes (max. 3 hours)
Sequential blood sampling through intravenous line, to determine the plasma and serum concentrations of:
Comparison between dGK and isocaloric control at the same time points (see below).
Time frame: Full 5 days of the study.
continuous glucose monitor (CGM; Abbott Libre Sense); continuous concentration in mM.
Time frame: Full 5 days of study
continuous measurement of cortisol (pg/ml) in passive sweat (EnLiSense device)
Time frame: Full 5 days of study
continuous measurement of melatonin (pg/ml) in passive sweat (EnLiSense device)
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Other
Pilot Study on Ketosis Impact on Signs and Symptoms of Schizophrenia and Bipolar Disorders
Acronym: KISSeS
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07005388
Mental Disorders, Psychosis
Lahore, Punjab Province, Pakistan
View Trial DetailsNCT05300633
Chemically-Induced Disorders, Mental Disorders
Toronto, Ontario, Canada
View Trial DetailsNCT03152032
Bipolar and Related Disorders, Mental Disorders
View Trial DetailsNCT07623928
Behavior, Emotional Regulation
London, Greater London, United Kingdom
View Trial Details